HOTLINE: Effective November 16, 2020

**New Test** **3003036** **Chlorpromazine, Serum or Plasma** **CHLORP SP**

**Methodology:** Quantitative Liquid Chromatography-Tandem Mass Spectrometry
**Performed:** Mon
**Reported:** 8 days

**Specimen Required:** Patient Prep: Timing of specimen collection: Predose (trough) draw - At steady state concentration.
Collect: Plain red. Also acceptable: Lavender ($K_2$ or $K_3$EDTA), pink ($K_2$EDTA), green (Heparin) or gray (Potassium oxalate or Sodium fluoride).
Specimen Preparation: Separate serum or plasma from cells within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Storage/Transport Temperature: Frozen.
Unacceptable Conditions: Whole blood. Hemolyzed specimens. Gel separator tubes, light blue (citrate) or yellow (SPS or ACD solution).
Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 14 days; Frozen: 14 days

**Reference Interval:**

| | |
|---|---|
| Therapeutic Range | 30-300 ng/mL |
| Toxic Level | Greater than or equal to 600 ng/mL |

**Interpretive Data:**
Chlorpromazine is a neuroleptic drug indicated for the treatment of schizophrenia, psychotic disorders and intractable hiccup. Chlorpromazine should not be used in patients who have epilepsy, Parkinson's disease, hypoparathyroidism, myasthenia gravis, and prostatic hypertrophy. Adverse effects may include drowsiness, hypotension, agranulocytosis, cardiac abnormalities, seizures and rare life-threatening effects, such as phenothiazine sudden death syndrome, and neuroleptic malignant syndrome. See Compliance Statement B: www.aruplab.com/CS

**CPT Code(s):** 80342 (Alt code: G0480)

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.